Charles River Laboratories

CRL

Market cap $10.8B

CRL Hedge Fund Activity: Q1 2026 in Review

557 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2026, worth a combined $9.86B — down 6.6% from $10.6B a quarter earlier.

Sellers outnumbered buyers: 86 funds closed out of CRL and 75 opened new positions — a net loss of 11 holders — while 199 trimmed existing stakes and 188 added.

The largest buyer was Fidelity Investments, adding an estimated $319M. The largest seller was Woodline Partners, cutting an estimated $63.6M.

• 557 institutional investors held Charles River Laboratories (CRL) as of Q1 2026, down from 580 in Q4 2025.
• Funds reported $9.86B of Charles River Laboratories stock for Q1 2026, down 6.6% quarter-over-quarter.
• 75 funds opened new Charles River Laboratories positions in Q1 2026 and 86 closed out, a net change of -11 holders.
• The largest Charles River Laboratories buyer in Q1 2026 was Fidelity Investments, an estimated $319M added.
• The largest Charles River Laboratories seller in Q1 2026 was Woodline Partners, an estimated $63.6M sold.

Based on aggregated 13F filings for Q1 2026.